Akero Therapeutics Inc logo

AKRO

Akero Therapeutics Inc

$11.92

Earnings Summary

Revenue
$0Mn
Net Profits
$-26.03Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Akero Therapeutics Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Akero Therapeutics Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Akero Therapeutics Inc’s net profit fell -72.49% since last year same period to $-26.03Mn in the Q1 2022. On a quarterly growth basis, Akero Therapeutics Inc has generated 19.72% jump in its net profits since last 3-months.

Net Profit Margins:

Akero Therapeutics Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Akero Therapeutics Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Akero Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.86
EPS Estimate Current Year
-0.86

Highlights

EPS Estimate Current Quarter:

Akero Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.86 - a -7.5% fall from last quarter’s estimates.

EPS Estimate Current Year:

Akero Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.86.

Key Ratios

Key ratios of the Akero Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.74
Return on Assets (ROA)
-0.33
Return on Equity (ROE)
-0.6
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Akero Therapeutics Inc’s earning per share (EPS) fell -72.09% since last year same period to -0.74 in the Q1 2022. This indicates that the Akero Therapeutics Inc has generated -72.09% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Akero Therapeutics Inc’s return on assets (ROA) stands at -0.33.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Akero Therapeutics Inc’s return on equity (ROE) stands at -0.6.

Dividend Per Share (DPS):

Akero Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-06
-0.8
-0.74
7.5%

Company Information

Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein, is currently being evaluated in Phase 2 clinical trials as a potential treatment for NASH. Akero is headquartered in South San Francisco.

Organisation
Akero Therapeutics Inc
Headquarters
601 Gateway Boulevard, South San Francisco, CA, United States, 94080
Employees
22
Industry
Health Technology